# A Mass Balance Study of [14C]ABSK021

> **NCT06186583** · PHASE1 · COMPLETED · sponsor: **Abbisko Therapeutics Co, Ltd** · enrollment: 6 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Pimicotinib（ABSK021）

## Key facts

- **NCT ID:** NCT06186583
- **Lead sponsor:** Abbisko Therapeutics Co, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-13
- **Primary completion:** 2024-05-30
- **Final completion:** 2024-07-30
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2024-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06186583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06186583, "A Mass Balance Study of [14C]ABSK021". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06186583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*